Kornimate/medical-research-clean huggingface dataset:
fear of falling in patients with chronic stroke

Conditions: Stroke

Summary: the aim of the study is to evaluate whether combining cognitive-behavioral therapy (cbt) with task-oriented balance training (tobt) is more effective than general health education (ghe) together with tobt in promoting fear of falling and reducing activity avoidance behavior.

the null hypothesis of this study will be that no significant difference in the efficacy of the two treatments (cbt + tobt; ghe + tobt) in promoting fear of falling and reducing fear avoidance behavior, and thus no significant difference in improving balance ability, reducing fall risks, improving health-related quality of life and community reintegration of people with stroke.

Eligibility criteria:
inclusion criteria: subjects will be included if they * are between 55 and 85 years of age; * have been diagnosed with a first unilateral ischemic brain injury or intracerebral hemorrhage by magnetic resonance imaging or computed tomography within the previous 1 to 6 years; * have been discharged from all rehabilitation services at least 6 months before program begins; * are able to work independently at least 10 meters with or without an assistive device; * have low balance self-efficacy (the activities-specific balance confidence scale score of \<80); * are able to score \> 7 out of 10 on the chinese version of abbreviated mental test; and * are able to follow instructions and provide written informed consent. exclusion criteria: subjects will be excluded if they * have any additional medical, cardiovascular, orthopaedic, or psychiatric or psychological condition that would hinder proper treatment or assessment; * have receptive dysphasia; * have significant lower peripheral neuropathy; or * are involved in a drug studies or other clinical trial.

Keywords: fear of falling fear avoidance behavior cognitive behavioral therapy rehabilitation
the effect of transcranial direct current stimulation (t-dcs) on the p300 component of event-related potentials in patients with chronic neuropathic pain due to crps or diabetic neuropathy

Conditions: Diabetic Neuropathies; Complex Regional Pain Syndrome Type II; Resistant Peripheral Neuropathic Pain; Chemotherapy Induced Pain Neuropathy

Summary: this is a controlled trial designed to determine short- and long-term effects of repeated tdcs on the p300 component of event-related evoked potentials in patients with chronic neuropathic pain due to complex regional pain syndrome (crps) or diabetic neuropathy as compared with healthy subjects.


Eligibility criteria:
inclusion criteria: * an affected upper limb or lower limb * diagnosed as : diabetic neuropathy, complex regional pain syndrome (crps), chemotherapy induced pain neuropathy (cipn), peripheral neuropathy. * have not responded to at least two medications of the following groups: opioids. tricyclics, ssri, snri, pregabalin, gabapentin, anticonvulsants. * positive lanss or crps criteria as follows: 1. continuing pain which is disproportionate to any inciting event or for crps diagnosis. 2. must report at least one symptom (symptoms here are reports by subject) in each of the four following categories: sensory, vasomotor, sudomotor/edema, motor/trophic. 3. must display at least one sign (signs here refer to objective observation/testing) in in each of the four following categories: sensory, vasomotor, sudomotor/edema, motor/trophic; * must meet resistant neuropathic pain criteria - pain that is neuropathic in characters that at least two neuropathic medications not from the same group have been tried for at least a month without improvement or severe side-effects were experienced. resistant neuropathic pain with a score for "average pain in the last 24 hours" ≥4 on a numeric scale 0-10 * tdcs naive exclusion criteria: * serious health problems other than crps or resistant neuropathic pain (e.g. uncontrolled hypertension, uncontrolled diabetes, heart failure) * pain/painful conditions unrelated to crps or neuropathic pain * pregnancy * history of seizures/epilepsy * implanted device (e.g. pacemaker) * active illicit drug/alcohol abuse * unable to follow directions or complete tools in hebrew * previous exposure to tdcs stimulation
hypofractionation with simultaneous integrated boost for early breast cancer

Conditions: Breast Cancer; Surgery; Adjuvant Radiotherapy

Summary: simultaneous integrated boost radiotherapy has been investigated in some malignant tumors and appears to be safe and feasible. however, hypofractionation with simultaneous integrated boost has been investigating in breast cancer. investigators initiated this phase ii prospective trial to analyse acute toxicity of hypofractionation with simultaneous integrated boost in patients with early breast cancer.

hypofractionated radiotherapy of the breast 15 × 2.70 gy with simultaneous integrated boost to the tumor bed (total dose within the boost volume 15 × 3.20 gy)

Eligibility criteria:
inclusion criteria: * histopathologically confirmed breast cancer operated by breast conserving surgery with clear margins * indication to adjuvant radiotherapy including boost radiotherapy * clearly identified primary tumor region preferably by radiopaque clips * primary wound healing after breast conserving therapy without signs of infection * pre- and/or postoperative chemotherapy and endocrine therapy were permitted when indicated * written informed consent exclusion criteria: * patients operated by mastectomy * no indication for boost radiation * resection margins positive for disease or insufficient identification of the boost volume * indication for radiotherapy of the regional lymph nodes * history of prior breast or thoracic radiotherapy * extended postoperative seroma at the beginning of radiotherapy * psychiatric disorders or psychological disabilities thought to adversely affect treatment compliance * pregnant or lactating patients and woman of child bearing potential, who lacked effective contraception
corneal astigmatism measurement study

Conditions: Astigmatism

Summary: to assess which commercially available measurement device is most accurate in measuring low (\< 1.0 d) degrees of corneal astigmatism.


Eligibility criteria:
inclusion criteria: * 50 years of age and older * proof of eye exam within the last 3 months * corneal astigmatism of \<1.0 diopter exclusion criteria: * prior history of refractive or corneal surgery * corneal trauma/disease * intraocular surgery

Keywords: corneal astigmatism low diopter corneal measurement corneal astigmatism < 1 diopter
ultraslow swl versus slow swl for renal stones with high attenuation value

Conditions: Renal Stones

Summary: ultraslow full-power swl versus slow power-ramping swl in renal stones with high attenuation value

to evaluate the efficacy of ultraslow rate of swl versus slow rate, power ramping swl for renal stones

Eligibility criteria:
inclusion criteria: * single renal stone less than or equal to 3 cm (2 cm for lower calyceal stones) * radio-opaque stone * high attenuation value (≥ 1000 hu) stone exclusion criteria: * abnormal renal anatomy * renal insufficiency * solitary kidney * coagulopathies * uncontrolled hypertension * renal artery or aortic aneurysm * active urinary tract infection * pregnancy * severe skeletal malformations (spinal deformity) precluding proper stone localization * skin to stone distance (ssd) \> 11 cm * bmi \> 30 kgm/m2

Keywords: renal stones swl high density stones ultraslow swl slow swl ramping pause
evaluating atorvastatin with omega-3 fatty acids in cardiovascular risk reduction in patients with type 2 diabetes

Conditions: Diabetes, Type 2

Summary: the aforrd trial is asking three important questions: what proportion of people with type 2 diabetes are likely to be treated satisfactorily with a fixed dose of a statin that lowers blood cholesterol levels to help reduce the risk of heart disease? to what extent do omega-3 fatty acids lower blood triglyceride levels when given with or without a statin? are there simple techniques that can help people to take their tablets on a regular basis?


Eligibility criteria:
inclusion criteria: * they have a diagnosis of type 2 diabetes mellitus for at least 3 months prior to entry. * are not known to have had a cardiovascular event exclusion criteria: * they are taking prescribed lipid lowering therapy * have triglycerides \> or = 8.0 mmol/l
multiple islet peptide administration in type 1 diabetes (multipept1de)

Conditions: Type 1 Diabetes

Summary: type 1 diabetes is an autoimmune disease in which the insulin secreting βcells of the pancreas are destroyed such that the patient is reliant on injection of insulin to adequately control blood glucose levels for the remainder of his/her life. the autoimmune process targets proteins in beta-cells which are termed autoantigens. this is a phase 1 study using a novel investigational medicinal product (imp) known as multipept1de in a study of safety and tolerability of administration in patients with recent onset type 1 diabetes. multipept1de is a mixture of peptides from islet auto antigens. the mixture has been designed to induce or restore immunological tolerance to the beta-cell and thus control or limit autoimmunity to protect beta-cells

recent onset type 1 diabetes patients will be randomized into 4 groups of 6 subjects and each group will receive 6 injections of either placebo, low, medium or high dose of imp; each injection is intradermal and spaced 1 month apart.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of type 1 diabetes * age 18-45 years * maximum of 4 years from diagnosis * evidence of ≥1 autoantibody against β-cell autoantigens * possession of the hla-dr4 (drb1\*0401) genotype * residual β-cell function (peak c-peptide \>200) exclusion criteria: * females who are pregnant, breast-feeding or not using adequate forms of contraception. * use of β-cell stimulants, immunosuppressive or immunomodulatory therapies, including systemic steroids within 1 month prior to randomization, any monoclonal antibody therapy given for any indication and any antigen-specific
oral care with colostrum for preventing late-onset sepsis in preterm infants

Conditions: Prematurity

Summary: this clinical trial aimed to evaluate the efficacy of the oral mother's colostrum administration for preventing late-onset sepsis in premature neonates during their stay in the neonatal intensive care unit. the investigators hypothesized that premature infants who receive oral mother's colostrum would have a lower incidence of late-onset sepsis and better hospital outcomes, compared to infants who receive a placebo.

the study was a randomized clinical trial, performed on very-low-birthweight premature newborns admitted to the neonatal intensive care unit of mataria teaching hospital after considering exclusion criteria. the enrolled newborns were randomly subdivided into two groups (1:1). the colostrum group received their mother's colostrum, and the placebo group received placebo (sterile water) using a standardized protocol. the newborns received 0.2 ml of the colostrum or placebo orally using a swab directed backward into the oropharynx (0.1 ml on either side of the oral cavity), starting during the first 24 hours of life and lasting for 5 days. vital signs were carefully monitored throughout the procedure. dosing was provided every 6 hours during the study period. all infants underwent follow-up from birth until discharge or death whichever came first. neonates were evaluated for occurrence of late-onset sepsis, death, and other clinical outcomes.

Eligibility criteria:
inclusion criteria: * very-low-birth-weight preterm newborns admitted to the neonatal intensive care unit within 24 hours after delivery * neonates with gestational age ≤ 34 weeks and weight ≤ 1500 grams exclusion criteria: * infants with severe gastrointestinal malformations. * infants with serious congenital anomalies or chromosomal abnormalities. * infants with signs of early-onset sepsis. * any contraindications for breastfeeding because of maternal conditions including active tuberculosis or aids, or treatment with medications excreted in breast milk.
the pivatal study -study of ventricular arrhythmia (vta) ablation in left ventricular assist device (lvad) patients

Conditions: Arrythmia; Cardiomyopathies

Summary: to investigate the effect of vta ablation at the time of lvad implant to see if it can reduce the incidence of vta after surgery

this study is a prospective, multicenter, open-label, randomized-controlled clinical trial enrolling 100 patients who are lvad candidates with a history of vta who will be randomized in a 1:1 ratio to intra-operative vta ablation vs. conventional medical management. comprehensive data on arrhythmia history, medication history will be collected in all randomized subjects. antiarrhythmic medical therapy will be handled in a uniform pattern between the two arms. randomized subjects will then be followed per routine schedules for post lvad implant. arrhythmia data, icd therapy, additional procedures including repeat surgery, ramp echocardiographic tests, right heart catheterization and catheter-based vta ablation will be collected. in addition, adverse events such as unplanned hospitalizations, emergency department visits, clinic visits, and all other aspects of health care utilization will be gathered. the planned average follow-up period will be 18 months.

Eligibility criteria:
inclusion criteria: * age \> 18 years * presence of advanced cardiomyopathy (of all intermacs classification) and eligible for lvad implant per the decision of the heart failure clinical team * implanted cardioverter defibrillator (icd) any time in past with remote monitoring or planned to undergo icd (or icm as an alternative, if an icd cannot be implanted for a clinical reason) implant within the index hospitalization for lvad implant * history of treated or monitored sustained (i.e., \>30 seconds in duration ) vt or vf episode within the past 5 years. exclusion criteria: * past successful vta ablation without recurrent vta prior to lvad implant (patients who continue to experience vta post ablation and pre lvad implant qualify to be enrolled) * participation in other clinical trials (observational registries are allowed with approval) * unable or unwilling to provide informed consent
memora-caregiver : risk factors of caregiver burden among patients with neurocognitive disorders or subjective cognitive complaint

Conditions: Neurocognitive Disorders

Summary: the investigators will investigate which patients' characteristics are associated with caregivers burden and its evolution for outpatients visiting a memory clinic, in particular how functional autonomy, behavioral and psychological symptoms as well as patients comorbidities can influence caregiver burden. the study will be conducted among outpatients with progressive cognitive complaint followed in a memory clinic and their primary caregiver. the investigators hypothesis that caregivers experience a higher burden due to disease symptoms such as impairment of functional autonomy, behavioral and cognitive impairment, whatever the aetiology of the cognitive decline.


Eligibility criteria:
inclusion criteria: * patients with a cognitive complaint, either expressed by the patient or one of their relatives, * patients at any stage of disease (cognitive complaint, mild cognitive impairment (mci) or dementia), * patients living in the community, * patients having an informal caregiver who will complete the questionnaire to assess the caregiver burden. exclusion criteria: -

Keywords: alzheimer's disease or related disorder comorbidity charlson comorbidity index caregiver burden cohort dementia behavioral disorders functional dependency
genetic basis for heterogeneity in response of plasma lipids to plant sterols

Conditions: Hyperlipidemia

Summary: the substantial range of individual responsiveness to plant sterols has important ramifications. marked differences across individuals in particular aspects of the cholesterol metabolic pathway must alter the impact of plant sterol consumption. as such, a pronounced need exists to understand the genetic and metabolic factors that explain the substantial degree of heterogeneity in response of lipid concentrations to plant sterols across individuals. the primary focus of this trial is to delineate the impact of differing cholesterol synthesis levels on response of ldl-c and other plasma lipids to plant sterol consumption. participants pre-identified as high or low endogenous cholesterol synthesizers, according to their screening level of lathosterol to cholesterol ratios, will be given ps or a placebo containing margarine to consume under supervision for 4 weeks in a crossover design. the trial will characterize the responsiveness of the participants' total, ldl, and hdl cholesterol, as well as triacylglycerol (tg) concentrations, to plant sterol consumption. this research will determine if cholesterol synthesis phenotype predicts the responsiveness of lipids to plant sterol consumption. variations in candidate genes involved in cholesterol metabolism will also be investigated in order to find associations with both cholesterol metabolism phenotypes and responsiveness of lipids to plant sterols. the output of this research will be to advance the knowledge of which genetic factors influence the degree of cardiovascular benefit derived from plant sterols through lipid lowering.


Eligibility criteria:
inclusion criteria: * fasting serum ldl cholesterol \>3.0 mmol/l * high or low lathosterol to cholesterol ratio exclusion criteria: * smoking * use of lipid lowering therapy * documented cardiovascular/atherosclerotic disease * inflammatory disease * diabetes * uncontrolled hypertension * kidney disease * liver disease * other systemic diseases * cancer * chronic alcohol consumption (\> 2 servings/day)

Keywords: cholesterol, plant sterols, non-response, snps,
analgesic efficacy of inter pleural ropivacaine road in post thoracotomy pain for oncologic surgery

Conditions: Postoperative Pain; Cancer

Summary: the purposes of this study are: 1. to determine the efficacy of inter pleural analgesia 2. to determine the plasmatic concentration of ropivacaine by inter pleural road


Eligibility criteria:
inclusion criteria: * thoracotomy for oncology thoracic surgery * secondary or primary cancer * american society of anesthesiology (asa) class 1 or 2 exclusion criteria: * ropivacaine hypersensibility * psychiatric disorders * incapacity of using visual analog scale

Keywords: thoracic surgery postoperative pain ropivacaine inter pleural analgesia
trials of ventilation assisted substance elimination via the lung - ethanol (vasel - ethanol)

Conditions: Alcohol Intoxication

Summary: this prospective, randomized control trial will use passive, isocapnic hyperventilation, applied via the clearmatetm device (thornhill medical, inc) versus controls receiving standard of care supportive management for severe alcohol intoxication to assess for enhanced ethanol elimination kinetics.


Eligibility criteria:
inclusion criteria: * intoxicated requiring admission to an emergency unit exclusion criteria: * liver or renal disease
length of hospital stay in laparoscopic transabdominal preperitoneal vs. open mesh repair in inguinal hernia: a randomised controlled trial

Conditions: Inguinal Hernia

Summary: to compare the mean length of hospital stay in laparoscopic trans abdominal preperitoneal repair versus open mesh repair in patients undergoing inguinal hernia repair with mesh.

a total of 334 patients of male gender with inguinal hernias of any side and asa score i and ii were included in the study. history of immunosuppression, associated with other abdominal hernias and recurrent hernia were excluded. 167 patients were in group a or laparoscopic trans abdominal preperitoneal repair group while 167 patients were in group b or open mesh repair. data regarding length of hospital stay from both groups was recorded by researcher himself on especially designed proforma.

Eligibility criteria:
inclusion criteria: * • age 18-60 years * inguinal hernias of any side as per operational definition * asa score i and ii exclusion criteria: * • h/o immunosuppression * associated with other abdominal hernias * h/o recurrent hernia
an open-label, multi-center study evaluating the validity, reliability, and responsiveness of a new female-specific angina questionnaire in women with chronic angina treated with ranolazine extended-release tablets (cvt 3041)

Conditions: Chronic Angina

Summary: according to the american heart association (aha) 2011 update of heart disease and stroke statistics, more than 9 million adult patients in the united states (us) have angina. this update also notes that a study of 4 national cross-sectional health examination studies found that, among americans 40 to 74 years of age, the age-adjusted prevalence of angina was higher among women than men. per acc/aha guidelines, the goal of antianginal therapy is the complete or near complete elimination of anginal chest pain and a return to normal activities and functional capacity. however, evaluating angina and responses to antianginal therapy is often not straightforward. this is particularly true of female patients with angina. because angina and response to antianginal therapy may differ in men and women, an instrument designed specifically to address symptomatology in women with angina could enhance our understanding and characterization of angina and responses to therapy in this population. the current study will evaluate the validity, reliability, and responsiveness of the newly developed women's ischemia symptom questionnaire (wisq) based on changes in angina symptomatology in a female angina population treated with ranolazine, compared with the widely used seattle angina questionnaire (saq).


Eligibility criteria:
inclusion criteria: * at least 3 months of documented history of stable angina or angina equivalents that is relieved by rest and/or sublingual ntg * taking antianginal therapy with beta-blockers, and/or dihydropyridine calcium antagonists, and/or long-acting nitrates for at least 4 weeks * mean angina frequency of ≥ 2 attacks per week * documented clinical evidence of ischemia exclusion criteria: * clinically significant hepatic impairment * uncontrolled clinically significant cardiac arrhythmias or a history of ventricular fibrillation, torsades de points, or other life-threatening ventricular arrhythmias not associated with acute coronary syndrome * treatment with strong cytochrome p450 inhibitors including ketoconazole, itraconazole, clarithromycin, nefazodone, nelfinavir, ritonavir, indinavir, or saquinavir * prior treatment with ranolazine * end-stage renal disease requiring dialysis * myocardial infarction or unstable angina